First Austrian biotech company to develop a cancer immunotherapy product through to market
Approval in 2017 of APN311 for treatment of pediatric neuroblastoma in EU and other countries,
US/Japan BLA filing in preparation
Respiratory drug candidate APN01 in clinical development
Oncology pipeline in clinical stages
Lead by highly experienced and motivated team with global background
‘Herd immunity’ and vaccine strategy The concept of ‘herd immunity’ is massively important in terms of disease transmission and overall efficacy of vaccine strategies. It relies on a certain proportion of a population having immunity against a disease, thus protecting those who are unable to receive vaccines. If vaccinated individuals stop the spread of infection,...
Treatment was safe and well tolerated and no drug-related severe adverse events were observed Significant improvement in mechanical ventilator-free Days and reduction in viral RNA load observed Biomarker development supports APN01’s mode of action against SARS-CoV-2 Investigators and experts recommend further development of APN01 in COVID-19 Press release (EN) | Presseaussendung (DE)
In light of the 21st annual #WorldCancerDay we would like to draw your attention to our work in fighting cancer. We at APEIRON Biologics AG want to make a contribution to people’s #wellbeing by developing the immune therapy APN401. APN401´s proprietary process brings in a paradigm change in cancer treatment to fight hematological and solid...